Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Nippon Ishin Co-Leader Shows Understanding of Off-Year Price Revisions
April 11, 2025
-
REGULATORY Bill to Nix Off-Year Scheme Politicized, Could Clear Lower House with Ishin Support
April 10, 2025
-
REGULATORY Amgen’s Imdelltra, CSL’s Andembry to Join NHI Price List on April 16
April 10, 2025
-
ORGANIZATION No. 1 Priority of Public-Private Council Must Be Drug Pricing: PhRMA Japan Chair
April 9, 2025
-
REGULATORY Public-Private Council Will Meet This Summer: Japan PM
April 8, 2025
-
REGULATORY Diet Begins Deliberations on Amendment of PMD Act, Bill to Repeal Off-Year Scheme
April 7, 2025
-
BUSINESS Jump in New Grad Hires Seen with Drug Makers in Japan: 2025 Poll
April 4, 2025
-
REGULATORY Japan Mulls Amendment of GCP Ordinance, Making Single IRBs a Rule
April 3, 2025
-
REGULATORY Japan Picks 14 “Loss” Products as Drugs with Highest Priority for Development
April 2, 2025
-
ORGANIZATION JPMA Renews Call for Social Security Not Reliant on Drug Price Cuts: FY2025 Policy
April 2, 2025
-
COMMENTARY How Will Japan Deal with Expected Cost Spike with Japan-Made Antibiotic APIs?
April 1, 2025
-
REGULATORY Japan Jittery over Mass Layoffs at FDA, though HHS Says Reviewers Won’t Be Affected
March 31, 2025
-
REGULATORY Japan Approves J&J’s Lazcluze, Genmab’s Tivdak, and More
March 28, 2025
-
BUSINESS Kyushu University Offshoot Eyes US Nod for Repositioned ROP Drug Candidate
March 27, 2025
-
BUSINESS J&J Submits Information Disclosure Requests to Japan Govt over Off-Year Revision
March 26, 2025
-
BUSINESS FRONTEO’s AI Engine Can Help Unearth Drug Targets, Predict Odds of Success: CTO
March 25, 2025
-
COMMENTARY Fair or Unfair? PMP Return Applied for First Time in Off-Year Revision
March 24, 2025
-
BUSINESS New BMS Japan Chief Vows Bold Resource Allocation towards Doubling of Sales
March 21, 2025
-
BUSINESS Datroway, Zeposia, and More Meds Now Available in Japan; Zepbound Launch Set for April 11
March 21, 2025
-
REGULATORY US Chamber Raises Japan’s Pharma Policy as Unfair Trade Practice, Prods Federal Govt for Action
March 19, 2025
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…